Cargando…
Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299692/ https://www.ncbi.nlm.nih.gov/pubmed/34796985 http://dx.doi.org/10.1111/dme.14746 |
_version_ | 1784751033668337664 |
---|---|
author | Peto, Tunde Akerele, Toks Sagkriotis, Alexandros Zappacosta, Sofia Clemens, Andreas Chakravarthy, Usha |
author_facet | Peto, Tunde Akerele, Toks Sagkriotis, Alexandros Zappacosta, Sofia Clemens, Andreas Chakravarthy, Usha |
author_sort | Peto, Tunde |
collection | PubMed |
description | INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti‐VEGF intravitreal injections in adults with treatment‐naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti‐VEGF injection‐, injection‐free‐ and total visits were assessed during the first and second years of treatment. RESULTS: Overall, 1606 patient eyes with DME were included, with no minimum follow‐up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti‐VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection‐free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years. CONCLUSIONS: The high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health‐related quality of life for patients with DME. |
format | Online Article Text |
id | pubmed-9299692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92996922022-07-21 Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study Peto, Tunde Akerele, Toks Sagkriotis, Alexandros Zappacosta, Sofia Clemens, Andreas Chakravarthy, Usha Diabet Med Research: Complications INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti‐VEGF intravitreal injections in adults with treatment‐naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti‐VEGF injection‐, injection‐free‐ and total visits were assessed during the first and second years of treatment. RESULTS: Overall, 1606 patient eyes with DME were included, with no minimum follow‐up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti‐VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection‐free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years. CONCLUSIONS: The high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health‐related quality of life for patients with DME. John Wiley and Sons Inc. 2021-12-15 2022-04 /pmc/articles/PMC9299692/ /pubmed/34796985 http://dx.doi.org/10.1111/dme.14746 Text en © 2021 Novartis Pharma AG. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research: Complications Peto, Tunde Akerele, Toks Sagkriotis, Alexandros Zappacosta, Sofia Clemens, Andreas Chakravarthy, Usha Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title | Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title_full | Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title_fullStr | Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title_full_unstemmed | Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title_short | Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study |
title_sort | treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the uk: a real‐world study |
topic | Research: Complications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299692/ https://www.ncbi.nlm.nih.gov/pubmed/34796985 http://dx.doi.org/10.1111/dme.14746 |
work_keys_str_mv | AT petotunde treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy AT akereletoks treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy AT sagkriotisalexandros treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy AT zappacostasofia treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy AT clemensandreas treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy AT chakravarthyusha treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy |